BIOMAT Database Logo BIOMAT Database Logo

Two-site immunoradiometric intact parathyroid hormone assay versus C-terminal parathyroid hormone in predicting osteodystrophic bone lesions in predialysis chronic renal failure. 1993

G Coen, and S Mazzaferro, and P Ballanti, and E Bonucci, and G A Cinotti, and G Fondi, and M Manni, and M Pasquali, and I Perruzza, and D Sardella
Chair of Nephrology, La Sapienza University, Rome, Italy.

Intact parathyroid hormone (iPTH) radioimmunoassay represents an important advancement in the measurement of serum PTH levels, permitting the evaluation of the actual rate of secretion of the parathyroid glands. The aim of the study was to compare the value of intact and C-terminal PTH measurements in predicting the osteodystrophic bone lesion in predialysis patients with chronic renal failure (CRF). We have studied 37 subjects with CRF who were receiving conservative treatment. In each subject a transiliac bone biopsy for histomorphometric examination was performed in addition to the assay of serum intact and C-terminal PTH, osteocalcin, and alkaline phosphatase. Serum C-terminal and intact PTH levels were closely correlated, both showing a high degree of correlation with serum osteocalcin. Similar degrees of correlation were observed between the two PTH assays and the histologic parameters osteoblastic surface (ObS/BS) and osteoclastic surface (OcS/BS). The evaluation of specificity and sensitivity of the two PTH assays in selecting patients with normal or pathologic histomorphometric parameters gave an equivalent number of false positive and negative cases. Based on discriminant analysis of histomorphometric parameters, intact PTH shows a higher discriminant power when compared with C-terminal PTH assay for the parameters OcS/BS and eroded surface (ES/BS), but without practical clinical value. In conclusion, in analogy to the short lived N-terminal PTH fragment assay, prediction of elementary hyperparathyroid bone lesions in predialysis CRF is not improved by the use of intact PTH as compared to the more traditional C-terminal assay.

UI MeSH Term Description Entries
D006962 Hyperparathyroidism, Secondary Abnormally elevated PARATHYROID HORMONE secretion as a response to HYPOCALCEMIA. It is caused by chronic KIDNEY FAILURE or other abnormalities in the controls of bone and mineral metabolism, leading to various BONE DISEASES, such as RENAL OSTEODYSTROPHY. Secondary Hyperparathyroidism,Hyperparathyroidisms, Secondary,Secondary Hyperparathyroidisms
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010281 Parathyroid Hormone A polypeptide hormone (84 amino acid residues) secreted by the PARATHYROID GLANDS which performs the essential role of maintaining intracellular CALCIUM levels in the body. Parathyroid hormone increases intracellular calcium by promoting the release of CALCIUM from BONE, increases the intestinal absorption of calcium, increases the renal tubular reabsorption of calcium, and increases the renal excretion of phosphates. Natpara,PTH (1-84),PTH(1-34),Parathormone,Parathyrin,Parathyroid Hormone (1-34),Parathyroid Hormone (1-84),Parathyroid Hormone Peptide (1-34),Hormone, Parathyroid
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D012080 Chronic Kidney Disease-Mineral and Bone Disorder Decalcification of bone or abnormal bone development due to chronic KIDNEY DISEASES, in which 1,25-DIHYDROXYVITAMIN D3 synthesis by the kidneys is impaired, leading to reduced negative feedback on PARATHYROID HORMONE. The resulting SECONDARY HYPERPARATHYROIDISM eventually leads to bone disorders. Renal Osteodystrophy,Renal Rickets,Rickets, Renal,CKD-MBD,Osteodystrophy, Renal,Chronic Kidney Disease Mineral and Bone Disorder,Osteodystrophies, Renal,Renal Osteodystrophies
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

G Coen, and S Mazzaferro, and P Ballanti, and E Bonucci, and G A Cinotti, and G Fondi, and M Manni, and M Pasquali, and I Perruzza, and D Sardella
A two-site immunoradiometric assay for intact parathyroid hormone.
July 1993, American clinical laboratory,
G Coen, and S Mazzaferro, and P Ballanti, and E Bonucci, and G A Cinotti, and G Fondi, and M Manni, and M Pasquali, and I Perruzza, and D Sardella
Clinical and laboratory evaluation of a two-site immunoradiometric assay for intact parathyroid hormone.
November 1988, Annals of clinical biochemistry,
G Coen, and S Mazzaferro, and P Ballanti, and E Bonucci, and G A Cinotti, and G Fondi, and M Manni, and M Pasquali, and I Perruzza, and D Sardella
Immunoradiometric and two-site assay of human parathyroid hormone.
May 1977, Calcified tissue research,
G Coen, and S Mazzaferro, and P Ballanti, and E Bonucci, and G A Cinotti, and G Fondi, and M Manni, and M Pasquali, and I Perruzza, and D Sardella
Serum intact parathyroid hormone concentration measured by a two-site immunoradiometric assay in normal subjects and patients with various parathyroid disorders.
February 1992, Endocrinologia japonica,
G Coen, and S Mazzaferro, and P Ballanti, and E Bonucci, and G A Cinotti, and G Fondi, and M Manni, and M Pasquali, and I Perruzza, and D Sardella
Two-site immunoradiometric assay of intact salmon calcitonin.
November 1992, Clinical chemistry,
G Coen, and S Mazzaferro, and P Ballanti, and E Bonucci, and G A Cinotti, and G Fondi, and M Manni, and M Pasquali, and I Perruzza, and D Sardella
Validity of intact plasma parathyrin measurements in chronic renal failure as determined by two-site immunoradiometric assays with N- or C-terminal capture antibodies.
November 1992, Clinical chemistry,
G Coen, and S Mazzaferro, and P Ballanti, and E Bonucci, and G A Cinotti, and G Fondi, and M Manni, and M Pasquali, and I Perruzza, and D Sardella
Immunoradiometric assay of parathyroid hormone.
March 1971, The Journal of endocrinology,
G Coen, and S Mazzaferro, and P Ballanti, and E Bonucci, and G A Cinotti, and G Fondi, and M Manni, and M Pasquali, and I Perruzza, and D Sardella
Circulating intact parathyroid hormone measured by a two-site immunochemiluminometric assay.
September 1987, The Journal of clinical endocrinology and metabolism,
G Coen, and S Mazzaferro, and P Ballanti, and E Bonucci, and G A Cinotti, and G Fondi, and M Manni, and M Pasquali, and I Perruzza, and D Sardella
[Studies on the half-life of C-terminal parathyroid hormone in chronic renal failure].
May 1987, Nihon Naibunpi Gakkai zasshi,
G Coen, and S Mazzaferro, and P Ballanti, and E Bonucci, and G A Cinotti, and G Fondi, and M Manni, and M Pasquali, and I Perruzza, and D Sardella
Serum levels of 1-84 and 7-84 parathyroid hormone in predialysis patients with chronic renal failure measured by the intact and bio-PTH assay.
January 2006, Nephron. Clinical practice,
Copied contents to your clipboard!